{"filings":[{"id":1997516,"accession_number":"0001104659-26-089293","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-07-31T21:17:23+00:00","items":["1.01","2.03"],"status":"ready","headline":"NW Bio enters $4.9M convertible note financing with Yorkville; also secures $50M standby equity facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$4.9M convertible promissory note, 12-month term, no interest, 5% OID, convertible at discount to market.","Yorkville also acquired warrant to purchase up to $2M shares at $0.205 per share.","Standby equity subscription agreement for up to $50M in common shares, available after note repaid/converted, 24-month term.","Proceeds for general corporate purposes including lead product and in-licensed portfolios.","Prior standby equity subscription agreement cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1729602,"accession_number":"0001104659-26-084743","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-07-17T23:48:55+00:00","items":["7.01"],"status":"ready","headline":"NWBO refutes false rumors of MHRA rejection; MHRA confirms DCVax-L MAA still under review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MHRA confirmed DCVax-L MAA for glioblastoma remains under initial review, not refused, withdrawn, or appealed.","Company categorically refutes false rumors of MHRA rejection and notes possible stock manipulation.","Rumors intensified after BNOS Annual Meeting where significant Phase 3 trial data were presented.","Company continues constructive interactions with MHRA; MAA progressing towards first regulatory decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91102,"accession_number":"0001104659-26-040260","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Northwest Biotherapeutics completes acquisition of UK CDMO Advent BioServices for ~$1.9M plus ~$8.3M payables","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.","Payment in installments over 2 years starting 3 months after close, with potential acceleration upon DCVax-L regulatory approval.","Related-party transaction: CEO Linda Powers controls seller; approved per company policies.","Company retired 12M shares and cancelled 5.5M stock options previously issued to Advent.","SEC granted waiver from providing Advent financial statements and pro forma info under Regulation S-X."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101015,"accession_number":"0001104659-26-004146","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NWBO settles 2020 option litigation; insurer pays $2.25M, 17% options cancelled","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement agreement entered Dec 12, 2025 for litigation over 2020 option awards.","Insurance carriers to pay $2.25 million to the company.","17% of challenged 2020 options will be cancelled.","Plaintiff may seek up to $3.5M in attorney fees, paid separately by insurers.","Court approval hearing set for 1:30 pm ET on March 16, 2026 in Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101014,"accession_number":"0001104659-26-000243","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.07","5.03","9.01"],"status":"ready","headline":"NWBO shareholders OK share increase to 2.6B, elect Pat Sarma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 1.7B to 2.6B; 89.65% of votes cast in favor.","Over 77% of total voting power represented at annual meeting; quorum present.","Pat Sarma elected as Class II director for three-year term with 81.1% of votes for.","Ratified Cherry Bekaert LLP as independent auditor for FY2025 (93.76% for).","Advisory vote on executive compensation approved with 77.23% of votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117356,"accession_number":"0001104659-25-114627","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NWBO enters $5M convertible note with Yorkville for Sawston facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Promissory note of $5M with YA II PN, Ltd. (Yorkville) for 12 months, no payments due until maturity.","Note carries 5% original issue discount, no interest, and convertible at a small discount to market price.","Monthly conversion limited to ~1/5 of note amount unless conversion price above $0.29.","Proceeds to fund construction/equipment for first Grade C manufacturing suite at Sawston, UK, plus operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117355,"accession_number":"0001104659-25-104812","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NW Biotherapeutics enters $5.5M loan agreement with Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan amount $5,505,000; maturity 22 months; interest 8% p.a.; 10% original issue discount.","No payments for first 8 months; 14 equal monthly installments start June 2026 at 110% pro rata principal plus interest.","Prepayment allowed with 10% charge; funds used for ongoing business operations.","Loan includes customary default provisions and potential acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117354,"accession_number":"0001104659-25-104427","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NWBO closes Advent BioServices acquisition; pays £1.4M + AP over 2 years; 19M securities revert","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Advent BioServices closed; Advent becomes wholly owned subsidiary.","No new shares issued; 13.5M shares and 5.5M options previously issued to Advent revert to NWBO.","Consideration: £1.4 million plus net accounts payable, paid in installments over two years starting 90 days post-closing.","Installment payments may accelerate upon regulatory approval of DCVax-L; NWBO receives fixed assets, cryostorage, and IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117353,"accession_number":"0001104659-25-102049","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NWBO files new Form S-3 shelf registration to replace expiring registration on Oct 25, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new S-3 shelf registration on October 23, 2025, effective for three years.","Existing shelf registration expires on October 25, 2025, necessitating replacement filing.","Action taken to maintain continuous ability to offer securities via shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117352,"accession_number":"0001104659-25-099196","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Northwest Biotherapeutics settles shareholder litigation over 2020 options; insurers to pay $2.25M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves Delaware Chancery litigation over 2020 option awards to management and directors.","17% of challenged options will be cancelled; company's insurers to pay $2.25 million to the company.","Definitive settlement documentation due within 30 days; plaintiff's amended complaint covered by deal.","Plaintiff intends to seek attorneys' fees and expenses, to be paid separately by insurers, subject to court approval.","Cash payment from insurers cannot be used for fee award; both settlement and fee require court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186526,"accession_number":"0001104659-24-131723","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.","Conversion at small discount to market price; limited to 1/6 of note per month unless conversion price above $0.315.","Standby equity subscription agreement allows company to require Yorkville to buy up to $50M of common shares after note repaid/converted.","Standby facility has 24-month term; no obligation to draw; company can cancel anytime after note repaid/converted.","Proceeds for general corporate purposes; Joseph Gunnar & Co. acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186525,"accession_number":"0001104659-24-113553","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.","Note matures in 24 months with no payments due until maturity; interest at 11% per annum.","Holder can convert into common stock at $0.30/share or non-dilutive financial instrument priced at $50,000.","Proceeds will be used for ongoing business operations; customary default provisions apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203103,"accession_number":"0001104659-24-085198","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"NW Bio investigates social media rumors; MHRA MAA review continues","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Company probing rumors linked to parties in federal NY lawsuit; coinciding with stock market developments.","Plans to pursue appropriate action against rumor sources; shareholders asked to report information.","MHRA review of Marketing Authorization Application in UK ongoing; inspections scheduled in US and UK.","CEO Linda Powers signed the disclosure; no financial guidance or earnings data provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203102,"accession_number":"0001104659-24-077718","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NWBO annual meeting re-elects directors, ratifies auditor and option awards, approves exec comp","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Dr. Alton L. Boynton (94.04% for) and Ambassador J. Cofer Black (93.01% for) as Class I directors for three-year terms.","Ratified Cherry Bekaert LLP as independent auditor for FY2024 with 92.73% of votes cast in favor.","Ratified 2020 option awards to named executive officers (88.13% for) and non-executive directors (88.05% for).","Advisory approval of 2023 executive compensation received 87.37% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219401,"accession_number":"0001104659-24-068314","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Northwest Biotherapeutics sells 8.125M shares at $0.40 to SIO Capital for $3.25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPA signed June 4, 2024; closing expected June 5, 2024.","Gross proceeds of $3,250,000 from sale of 8,125,000 shares of common stock.","Proceeds to be used for ongoing business operations.","SIO Capital Management LLC is the purchaser; Joseph Gunnar & Co. acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219400,"accession_number":"0001104659-24-056424","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Northwest Biotherapeutics enters $11M loan agreement with Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan principal of $11,005,000; maturity 22 months; repayments begin Dec 26, 2024.","14 equal monthly installments at 110% of pro rata plus accrued interest (8% per annum).","10% original issue discount; prepayment allowed with 10% charge.","Proceeds fund business ops, construction of first grade C lab in Sawston UK, long lead-time equipment, Flaskworks prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239230,"accession_number":"0001104659-24-037901","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Northwest Biotherapeutics appoints Pat Sarma as Class II director effective March 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pat Sarma appointed as Class II director and to Audit, Compensation, and Conflicts Committees.","No arrangements or related-party transactions in connection with his appointment.","Compensation will be on same basis as other non-employee directors.","Appointment date: March 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239229,"accession_number":"0001104659-24-034527","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jerry Jasinowski retires from Northwest Biotherapeutics Board at age 85","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jerry Jasinowski retired from Board on March 8, 2024, after more than a decade of service.","Retirement due to health reasons, not due to any disagreement with company's operations.","No replacement director named; board size decreases by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256733,"accession_number":"0001104659-23-119165","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NWBO enters $11M loan with Streeterville Capital; 8% interest, 24-month maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan amount $11,005,000 from Streeterville Capital; 24-month maturity; repayments begin Nov 2024.","Interest rate 8% per annum; 10% original issue discount; prepayment allowed with 10% charge.","Loan amortized in 12 equal monthly installments at 110% of pro rata principal plus accrued interest.","Proceeds used for ongoing business operations; customary default provisions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312057,"accession_number":"0001104659-23-030141","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Northwest Biotherapeutics secures $11M loan from Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of $11,005,000 from Streeterville Capital, maturity 22 months, repayments start Nov 2023.","Interest at 8% per annum, with 10% original issue discount; prepayment allowed with 10% charge.","Proceeds for Sawston facility buildout, product approval preparation, and general operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312056,"accession_number":"0001104659-23-003846","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Northwest Biotherapeutics increases authorized common shares from 1.2B to 1.7B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment with Delaware Secretary of State on January 9, 2023.","Authorized shares of common stock increased by 500 million to 1.7 billion; par value remains $0.001.","No concurrent offering or use of proceeds disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312055,"accession_number":"0001104659-23-001886","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Northwest Biotherapeutics shareholders approve all six proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Linda F. Powers and Navid Malik with 97.2% and 97.5% of votes cast respectively.","Ratified Cherry Bekaert LLP as auditor for FY2022 with 98.8% of votes cast.","Approved increase of authorized common shares from 1.2B to 1.7B with 95% of votes cast (73.8% of outstanding common).","Approved advisory say-on-pay for 2021 executive compensation with 91.9% support.","Ratified 2020 option awards to executives and independent directors with over 90% approval each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348147,"accession_number":"0001104659-22-082813","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"NWBO eliminates Series A/B Preferred, creates Series C Preferred (10M shares)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Elimination for Series A and B Preferred Stock on July 20, 2022; no shares outstanding.","Created Series C Preferred Stock with 10M shares, $0.001 par value, rights and preferences established.","Series C created from authorized but unissued preferred shares; effective July 20, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402277,"accession_number":"0001104659-21-144456","cik":1072379,"company_name":"NORTHWEST BIOTHERAPEUTICS INC","ticker":"NWBO","form_type":"8-K","filed_at":"2021-11-29T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"NWBO enters $15M loan with Streeterville; conversion right tied to Phase III data","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of $15M from Streeterville Capital, LLC; 22-month maturity, 8% interest, 10% OID.","No payments first 8 months, then 14 equal monthly principal installments at 110% pro rata plus interest.","Lender gets springing right upon top-line data from DCVax-L Phase III to convert balance into shares at 12% discount to next private placement.","Funds will be used for ongoing business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":348388885.3971291,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}